Department of Cardiology, Petz Aladár County Teaching Hospital, Vasvári Pál str. 2-4, 9024, Győr, Hungary.
Am J Cardiovasc Drugs. 2017 Oct;17(5):361-373. doi: 10.1007/s40256-017-0221-8.
The role of β-adrenoceptor antagonists (β-blockers) in cardiovascular therapy has been subject to diverse trends and changes over the decades. With the advent of a wide variety of excellent drugs for the treatment of antihypertension, β-blockers have been relegated from the first-line treatment of essential hypertension. However, they remain the drugs of first choice in recommendations from the respective medical societies for heart failure, coronary artery disease, and atrial fibrillation as well as in hypertension complicated with heart failure, angina pectoris, or prior myocardial infarction. When indicated, cardioselective β-blockers should be prescribed in patients with diabetes mellitus or chronic obstructive pulmonary disease. We review the available evidence for the use of β-blockers in clinical conditions in which recommendations can be made for everyday practice.
β-受体阻滞剂（β 阻滞剂）在心血管治疗中的作用在过去几十年中经历了多种趋势和变化。随着各种治疗高血压的优秀药物的出现，β 阻滞剂已从原发性高血压的一线治疗药物中降级。然而，它们仍然是相关医学协会推荐用于心力衰竭、冠心病和心房颤动以及高血压合并心力衰竭、心绞痛或既往心肌梗死的首选药物。在有指征的情况下，应在患有糖尿病或慢性阻塞性肺疾病的患者中开具有心脏选择性的β 阻滞剂。我们回顾了在有推荐意见的临床情况下使用β 阻滞剂的可用证据，以指导日常实践。
